Single-arm Study to Evaluate the Safety and Efficacy of Pazopanib, in Subjects With FGFR2 Amplification, FGFR2 Mutation Refractory Solid Tumors
NACompletedINTERVENTIONAL
Enrollment
2
Participants
Timeline
Start Date
October 8, 2015
Primary Completion Date
July 30, 2017
Study Completion Date
February 28, 2018
Conditions
Refractory Solid Tumors
Interventions
DRUG
pazopanib
Trial Locations (1)
135-710
Samsung Medical Center, Seoul
All Listed Sponsors
lead
Samsung Medical Center
OTHER
NCT02450136 - Single-arm Study to Evaluate the Safety and Efficacy of Pazopanib, in Subjects With FGFR2 Amplification, FGFR2 Mutation Refractory Solid Tumors | Biotech Hunter | Biotech Hunter